Press releases
- Press releases
- Browse
Press releases
Probiodrug AG grants Ferring BV and its sublicensee, Ortho-McNeil Pharmaceuticals, a Johnson & Johnson company, a non-exclusive license to develop inhibitors of dipeptidyl peptidase IV (DP IV). More
STOWIC's IP and processes have been acquired by United Pharmaceuticals of Jordan. More
Vernalis Factsheet More
Strong progress made in advancing our key drug development programs More
More patients reach target LDL-Cholesterol levels with Crestor More
More than 10,000 patients now involved in on-going studies of Crestor More
MONTREAL, PQ - ConjuChem Inc. (TSX:CJC), today announced the initiation of healthy volunteer dosing as part of a Phase I clinical trial for DAC:GLP-1TM (CJC-1131), a compound under development for the treatment of Type 2 diabetes. More
Ferring will collaborate with Ortho-McNeil to research and develop Ferring's inhibitors inhibitors of dipeptidyl peptidase IV (DP IV) for use in the treatment of diabetes and obesity. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Feb 2009 - 160 pages - $1,390
Mar 2011 - 43 pages - $5,700
May 2010 - 71 pages - $2,500
May 2010 - 70 pages - $2,500
May 2010 - 72 pages - $2,500
May 2010 - 75 pages - $2,500
May 2010 - 76 pages - $2,500
Apr 2010 - 72 pages - $2,500
Jun 2011 - 44 pages - $5,700
May 2010 - 73 pages - $2,500
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us